(Press-News.org) BOSTON—Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Prediabetes is well known to increase the risk of developing diabetes; however, information about other complications of prediabetes in Latin America was limited before this study,” said study researcher Carlos Fermin-Martinez, M.D., of the National Autonomous University of Mexico in Mexico City, Mexico. He is also with the National Institute of Geriatrics in Mexico City, which funded this project. “Our results are particularly relevant for the population of Mexico, where the prevalence of prediabetes is rising at an alarming rate.”
The researcher studied data from 115,919 adults ages 35 to 74 without diabetes who participated in the Mexico City Prospective Study (MCPS). Participants entered the study between 1998 and 2004 and received follow up until January 1, 2021. The MCPS received funding primarily from the Mexican Health Ministry and from the United Kingdom’s Wellcome Trust foundation.
More than one in four study participants (26%) had prediabetes as defined by the American Diabetes Association (ADA), Fermin-Martinez reported. The ADA defines prediabetes as a hemoglobin A1C concentration of 5.7 to 6.4 percent. An A1C test measures average blood sugar levels over three months.
When Fermin-Martinez evaluated prevalence using a stricter definition of prediabetes as an A1C of 6% to 6.4%, only 7% of participants had the precursor to diabetes. This definition came from the International Experts Committee, appointed by widely recognized diabetes associations in 2008 to give a consensus about A1C use for diagnosing diabetes.
Compared with participants whose blood sugar levels were normal, participants with the stricter definition of prediabetes had 2.6 times the risk of dying of acute complications of diabetes at ages 40 to 74. They also had 1.6 times, or 60%, increased risk of dying prematurely due to kidney disease. Although the risk of dying of heart disease increased when the researcher used the international committee’s A1C cutoff for prediabetes, there was no significant difference with the ADA cutoff, Fermin-Martinez said.
“Eventual development of diabetes most likely accounts for a large percentage of deaths for people with prediabetes,” he said. “We could significantly reduce premature mortality in the Mexican population by identifying and treating prediabetes early on.”
Approximately 80% of persons with prediabetes do not know they have it, according to the U.S. Centers for Disease Control and Prevention (CDC). In the U.S., up to 35% of Hispanic adults have prediabetes, the CDC estimates.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
Prediabetes raises Mexicans’ risk of dying prematurely of heart or kidney disease
2024-06-01
ELSE PRESS RELEASES FROM THIS DATE:
GLP-1 has the power to change taste sensitivity in women with obesity
2024-06-01
BOSTON—Semaglutide improved taste sensitivity, changed gene expression in the tongue that’s responsible for taste perception, and changed the brain’s response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“People with obesity often perceive tastes less ‘intensely,’ and they have an inherently elevated desire for sweet and energy-dense food,” said Mojca Jensterle Sever, Ph.D., of the University Medical Centre in Ljubljana, Slovenia.
Jensterle Sever and colleagues designed a proof-of-concept study on the impact of GLP-1 ...
Race and social vulnerability impact glycemic control in people with diabetes
2024-06-01
BOSTON—People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“As of 2021, 29.7 million people were living with diabetes, contributing to significant morbidity across the population. Despite advances in diabetic care, marginalized populations bear an increased burden of diabetic complications,” said study author Jennifer Tich, M.D., from Internal Medicine-Pediatrics R3 at the University of Rochester in Rochester, N.Y.
Tich and colleagues identified ...
Higher blood concentrations of testosterone are associated with reduced risk of developing type 2 diabetes in men under 65
2024-06-01
BOSTON—Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“A low blood testosterone concentration is an independent risk factor for developing type 2 diabetes, and high levels of testosterone appear protective against the development of type 2 diabetes,” said lead researcher ...
Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening
2024-06-01
About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be achieved by lowering the fecal immunochemical test positivity threshold, without additional mt-sRNA testing. The findings are similar to previous observations for multitarget stool DNA testing.
Corresponding Author: To contact the corresponding author, Hermann Brenner, M.D., M.P.H., email h.brenner@dkfz.de.
To access the embargoed study: Visit our For The Media website ...
Revolutionary brain-to-brain technology boosts brain-computer interface performance
2024-06-01
A groundbreaking study from Tsinghua University in collaboration with Imperial College London has unveiled a novel technique that significantly enhances brain-computer interface (BCI) systems by integrating brain-to-brain interactions among users. This innovative approach, detailed in a new study published in the journal Cyborg Bionic Systems, demonstrates the potential for improved BCI performance in applications such as rehabilitation and multitasking devices.
The research, led by Dr. Tianyu Jia and a team of interdisciplinary scientists, explored the effects of social interactions, ...
Insurance often denies GLP-1 medications for teens with type 2 diabetes, obesity
2024-06-01
BOSTON—Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
The medications, called GLP-1 receptor agonists (GLP1Ra), are often denied despite being approved by the U.S. Food and Drug Administration, especially if children do not have type 2 diabetes, the researchers found.
GLP1Ra drugs include liraglutide (Victoza, Saxenda). The researchers ...
Childhood stress linked with earlier substance use in male and female teens
2024-06-01
BOSTON—Stress during childhood is associated with earlier substance use in male and female adolescents, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. Traumatic events may increase substance use risk for males, while environmental stress and early puberty may increase the risk for females, the researchers found.
Early life stress is children’s experiences of abuse, neglect and conflict. Approximately 20% of adolescents in the United States have experienced early life stress at some point, and these experiences ...
Childhood sedentariness may cause premature liver damage in young adulthood
2024-06-01
BOSTON—Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, a new study finds. The research findings will be presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass and published in Nature’s npj Gut and Liver.
“We found that this relationship between sedentariness and liver damage is likely causal,” said lead researcher Prof. Andrew Agbaje, M.D., M.P.H., Ph.D., of the University of Eastern Finland ...
Experimental therapy shows promise in pancreatic cancer clinical trial
2024-06-01
WASHINGTON --- Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
The findings were presented at the American Society of Clinical Oncology 2024 annual meeting in Chicago on June 1, 2024 (LBA4132).
BXCL701, made by BioXcel Therapeutics, is ...
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
2024-06-01
Boston – Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. The studies support future research in these potential breakthroughs where treatment options may be limited. The research teams will present their findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 global oncology professionals.
These findings are among more than 80 studies presented at ASCO that ...